News
Latest press releases – plus an archive of press releases, thus recording milestones and key facts in Sunstone’s history.
IO Biotech Completes Oversubscribed EUR 127 Million Series B Financing to Accelerate Clinical Programs in Oncology
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune- modulating anti-cancer therapies based on its proprietary T-win® technology, announced today that it has raised EUR 127 million in Series B financing. Press inquiries should be adressed...
Ascelia Pharma gets US patent for 2nd generation Mangoral
Ascelia Pharma AB (publ) (ticker: ACE) today announced that the US Patent Office (USPTO) has issued a new patent covering a second-generation formulation of lead drug candidate Mangoral, currently in the pivotal Phase 3 study SPARKLE. The new patent further...
MinervaX raises upsized EUR 47.4M Series B to advance its novel Group B Streptococcus vaccine through mid-stage clinical trials
MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington...
The FDA grants IO Biotech breakthrough therapy designation for IO102 and IO103 in combination with anti-PD-1 in unresectable/metastatic melanoma
IO Biotech today announced that the FDA has granted breakthrough therapy designation for a combination of the potential therapy IO102 and IO103 with anti-PD-1 mAb for patients with unresectable/ metastatic melanoma. Press inquiries should be adressed to:...
Kim Stratton, CEO, resigns from Orphazyme
Orphazyme A/S (ORPHA.CO) (“Orphazyme”), a late-stage biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases, today announces that Kim Stratton has decided to resign from Orphazyme following a...
Sunstone announces new investment in neuropsychiatric company Synendos Therapeutics
Copenhagen, 12 November 2020 – Sunstone Life Science Ventures today announces it has invested in a new portfolio company, Synendos Therapeutics AG (“Synendos”), a biopharmaceutical company dedicated to developing novel therapeutics for the treatment of a wide range of...